ImmunoCellular Therapeutics (IMUC) Ramps on New Buy Rating

September 6, 2012 9:47 AM EDT Send to a Friend
Shares of ImmunoCellular Therapeutics (NYSE: IMUC) are on the move after Maxim ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login